Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

Cash, cash equivalents and investments were $2.67B as of September 30, 2025, compared to $3.135B as of December 31, 2024. “We remain laser-focused on advancing the development of VAX-31, the broadest-spectrum pneumococcal conjugate vaccine, PCV, in the clinic, given its potential to substantially broaden protection against both currently circulating and historically prevalent serotypes compared to currently available PCVs,” said CEO Grant Pickering. “For the adult indication, we expect to initiate the VAX-31 pivotal, non-inferiority study in December, with additional Phase 3 study initiations in 2026. For the infant indication, the final data from our VAX-24 infant Phase 2 dose-finding study are consistent with the previously reported positive interim data and show that VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. These results further validate our rationale for exploring higher doses in the ongoing VAX-31 infant Phase 2 dose-finding study. Together, the growing body of data from both the adult and infant programs reinforces our conviction that VAX-31 has a potential best-in-class profile.”